论文部分内容阅读
目的探讨hMLH1、hMSH2单核苷酸多态性(SNPs)与非小细胞肺癌(NSCLC)铂类为主的方案化疗后生存期的关系。方法经病理学确诊的晚期NSCLC患者120例,采用铂类为主的两药联合化疗方案,化疗前采集患者的外周血。根据cDNA芯片原理制作目的基因芯片,利用双色荧光探针杂交进行多态性的基因分型,并随机抽取10%的样本进行测序来验证该方法的准确性,比较不同基因型与铂类药物化疗后生存期的关系。结果成功进行基因分型,野生型、杂合型和突变型的叠加荧光分别显示为绿色、黄色和红色,与基因测序结果完全吻合。中位随访11个月。携带hMLH1 T/T和T/A+A/A基因型患者铂类化疗后中位生存期(MST)为11.2个月和14.2个月,1年、2年、3年生存率分别为40.5%、11.9%、7.1%和63.6%、9.1%、4.5%(P>0.05);携带hMSH2 T/T和T/C+C/C基因型患者MST、1年生存率分别为13.4个月、57.7%和10.7个月、33.3%(P<0.05),2年及3年生存率差异均无统计学意义(P>0.05)。结论 hMLH1、hMSH2基因多态性与NSCLC患者铂类药物化疗后的生存期无显著相关性。
Objective To investigate the relationship between hMLH1, hMSH2 single nucleotide polymorphisms (SNPs) and the survival of non-small cell lung cancer (NSCLC) platinum-based chemotherapy after chemotherapy. Methods One hundred and twenty patients with advanced NSCLC diagnosed by pathology were treated with platinum-based combination chemotherapy and peripheral blood of patients were collected before chemotherapy. According to the principle of cDNA microarray, the target gene chip was made, the genotyping of the polymorphism was carried out by two-color fluorescent probe hybridization, and 10% samples were randomly selected to be sequenced to verify the accuracy of the method. The comparison of different genotypes with platinum drug chemotherapy After the survival of the relationship. Results The genotyping was successful. The wild-type, heterozygous and mutant superimposed fluorescence showed green, yellow and red, respectively, which were in good agreement with the results of sequencing. The median follow-up of 11 months. The median survival time (MST) of patients with hMLH1 T / T and T / A + A / A genotypes after platinum chemotherapy was 11.2 months and 14.2 months, and the 1-year, 2-year and 3-year survival rates were 40.5% , 11.9%, 7.1% and 63.6%, 9.1% and 4.5% respectively (P> 0.05). The 1-year survival rates of MST patients with hMSH2 T / T and T / C + C / C genotypes were 13.4 months and 57.7 % And 10.7 months, 33.3% (P <0.05). There was no significant difference in two-year and three-year survival rates (P> 0.05). Conclusion There is no significant correlation between the hMLH1 and hMSH2 gene polymorphisms and the survival of NSCLC patients after platinum chemotherapy.